Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
118.56
+0.80 (+0.68%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign
January 02, 2024
The company inked an expanded collaboration deal with Novartis to test out gene therapies.
Via
Investor's Business Daily
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
December 28, 2023
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f
Via
Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
(NVS) - Analyzing Novartis's Short Interest
December 20, 2023
Via
Benzinga
(NVS) - Analyzing Novartis's Short Interest
December 01, 2023
Via
Benzinga
These 3 Big Pharma Stocks Are Making Big Plays With AI
December 22, 2023
Opportunity is in the air with AI, and these pharma giants are seizing the moment.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...
Via
Benzinga
Exposures
Product Safety
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...
Via
Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c
Via
Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now.
Via
InvestorPlace
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...
Via
Benzinga
Exposures
Product Safety
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease
December 11, 2023
Novartis AG (NYSE: NVS) announced
Via
Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
December 07, 2023
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
Via
Investor's Business Daily
Novartis' Rare Blood Disorder Therapy Scores FDA Approval
December 06, 2023
The FDA approved Novartis AG's (NYSE
Via
Benzinga
Exposures
Product Safety
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
November 30, 2023
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment...
Via
SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
November 29, 2023
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Via
SBWire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Healthcare Stocks to Pick Up Before the Year-End Rally
November 28, 2023
Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending
Via
InvestorPlace
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off
November 28, 2023
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...
Via
Benzinga
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028
November 27, 2023
Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory...
Via
SBWire
Exposures
Product Safety
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
November 22, 2023
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.
Via
Investor's Business Daily
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Diversifying Your Portfolio With Plant-Based Options
November 16, 2023
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...
Via
Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.